Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...

Mounjaro and Zepbound generated combined sales of $6.15 billion in the first quarter of 2025, accounting for around 48% of the company’s total revenues. Both drugs enjoy increasing market share ...

Mounjaro and Zepbound generated combined sales of $6.15 billion in the first quarter of 2025, accounting for around 48% of the company’s total revenues. Both drugs enjoy increasing market share ...

Though sales of Mounjaro and Zepbound were below expectations in the second half of 2024, hurt by slower-than-expected growth and unfavorable channel dynamics, their sales picked up in the first ...

Two growth stocks in the healthcare industry stand out in particular. Here is what you need to know about each one and why ...

Joe Gebbia, a confidant of the technology billionaire and a Tesla director, is also a leader of the federal cost-cutting team ...

Artificial intelligence (AI) has the potential to transform several different areas of the healthcare industry.

Eli Lilly surpasses expectations with Zepbound and Mounjaro sales. Zepbound’s strong market entry and Mounjaro’s surging sales. Market reacts positively, Eli Lilly becomes a pharmaceutical giant.

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

INDIANAPOLIS — Eli Lilly filed lawsuits against compounding pharmacies and an Indianapolis weight loss company over the use of Zepbound and Mounjaro. On April 1, 2025, Lilly filed lawsuits against two ...